{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:41:34Z","timestamp":1791308494521,"version":"4.3.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.ymgme.2007.09.013","type":"journal-article","created":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T03:37:26Z","timestamp":1196480246000},"page":"112-128","source":"Crossref","is-referenced-by-count":451,"title":["Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry"],"prefix":"10.1016","volume":"93","author":[{"given":"William R.","family":"Wilcox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Banikazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Marodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breunig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta M.","family":"Lemay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2007.09.013_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease: ceramide trihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2007.09.013_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08035320510028076","article-title":"Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.09.013_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08035320510028058","article-title":"Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy","volume":"94","author":"Shah","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.09.013_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2007.09.013_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2002.tb03110.x","article-title":"Pathophysiology and assessment of neuropathic pain in Fabry disease","volume":"91","author":"Schiffmann","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.09.013_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy","volume":"19","author":"Dutsch","year":"2002","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-003-1133-x","article-title":"Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease","volume":"250","author":"Stemper","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib11","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0002-9343(80)90224-7","article-title":"Chronic airflow obstruction in Fabry\u2019s disease","volume":"68","author":"Rosenberg","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib12","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","article-title":"Pulmonary involvement in Fabry disease","volume":"155","author":"Brown","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000087675","article-title":"Cardiopulmonary exercise testing in Fabry disease","volume":"72","author":"Bierer","year":"2005","journal-title":"Respiration"},{"key":"10.1016\/j.ymgme.2007.09.013_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2007.09.013_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.09.013_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2007.09.013_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just \u201ccarriers,\u201d but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib21","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2007.09.013_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2007.09.013_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2007.09.013_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.09.013_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease","volume":"27","author":"Dehout","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.09.013_bib28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2007.09.013_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2007.09.013_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CNP64281","article-title":"Identification of Fabry\u2019s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients","volume":"64","author":"Tanaka","year":"2005","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2007.09.013_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfl528","article-title":"A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population","volume":"22","author":"Merta","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2007.09.013_bib36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2002.tb03106.x","article-title":"Isolated cardiac manifestations in Fabry disease: the UK experience","volume":"439","author":"Sachdev","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.09.013_bib39","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2007.09.013_bib40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2007.09.013_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib42","unstructured":"SAS Institute Inc. SAS Procedures Guide, Version 8. SAS Institute Inc., Cary, NC. 1999."},{"key":"10.1016\/j.ymgme.2007.09.013_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2002.tb03109.x","article-title":"Pain assessment: the advantages of using pain scales in lysosomal storage diseases","volume":"91","author":"Cleeland","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2007.09.013_bib44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2007.09.013_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2007.09.013_bib46","series-title":"SF-36\u00ae Health Survey Manual and Interpretation Guide","author":"Ware","year":"1993"},{"key":"10.1016\/j.ymgme.2007.09.013_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Quality Life Res."},{"key":"10.1016\/j.ymgme.2007.09.013_bib48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.gim.0000223545.63012.5a","article-title":"Comparison of health-related quality of life between heterozygotes women with Fabry disease, a healthy control population, and patients with other chronic disease","volume":"8","author":"Street","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Quality Life Res."},{"key":"10.1016\/j.ymgme.2007.09.013_bib50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/rmed.2001.1274","article-title":"Relationship between patient and disease characteristics, and health-related quality of life in adults with asthma","volume":"96","author":"Erickson","year":"2002","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib51","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0272-6386(03)00361-5","article-title":"Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients","volume":"41","author":"Lowrie","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2007.09.013_bib52","first-page":"1706","article-title":"How does quality of life of patients with systemic lupus erythematosis compare with that of other common chronic illnesses?","volume":"32","author":"Jolly","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new predictive equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib54","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2007.09.013_bib55","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2007.09.013_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2007.09.013_bib57","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2007.09.013_bib58","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2007.09.013_bib59","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00392-002-0848-5","article-title":"The heart in Anderson Fabry disease","volume":"91","author":"Kampmann","year":"2002","journal-title":"Z. Kardiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib60","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib61","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2005.09.071","article-title":"Gender, age, society, culture, and the patient\u2019s perspective in the functional gastrointestinal disorders","volume":"130","author":"Chang","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymgme.2007.09.013_bib62","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0895-4356(98)00086-9","article-title":"Methods for validating and norming translations of health status questionnaires: The IQOLA Project approach","volume":"51","author":"Gandek","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib63","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00083-3","article-title":"Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Wagner","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib64","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0895-4356(98)00107-3","article-title":"The factor structure of the SF-36 health survey in 10 countries: results from the IQOLA Project","volume":"51","author":"Ware","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymgme.2007.09.013_bib65","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719207004143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719207004143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T08:56:45Z","timestamp":1546419405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719207004143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1096719207004143"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2007.09.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}